Exact Sciences (NASDAQ: EXAS) reported Q3 EPS of ($0.36), $0.06 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $28.1 million versus the consensus estimate of $25.1 million.

• reported completing 68,000 Cologuard tests vs consensus of 65,400 tests

GUIDANCE:

Exact Sciences sees FY2016 revenue of $93-95 million, versus the consensus of $90.9 million.

• reiterated our FY 2016 guidance of completing approximately 240,000 Cologuard tests

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.